GAMMA Investing LLC Buys 13,270 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

GAMMA Investing LLC increased its holdings in SpringWorks Therapeutics (NASDAQ:SWTX) by 13,138.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,371 shares of the company’s stock after acquiring an additional 13,270 shares during the period. GAMMA Investing LLC’s holdings in SpringWorks Therapeutics were worth $590,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in SWTX. Rhumbline Advisers raised its holdings in shares of SpringWorks Therapeutics by 2.3% in the 4th quarter. Rhumbline Advisers now owns 101,904 shares of the company’s stock worth $3,682,000 after acquiring an additional 2,251 shares during the last quarter. State of New Jersey Common Pension Fund D raised its holdings in shares of SpringWorks Therapeutics by 19.3% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 55,343 shares of the company’s stock worth $2,000,000 after acquiring an additional 8,954 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of SpringWorks Therapeutics by 20.2% in the 4th quarter. Principal Financial Group Inc. now owns 1,103,858 shares of the company’s stock worth $39,882,000 after acquiring an additional 185,413 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in SpringWorks Therapeutics in the 4th quarter valued at about $45,000. Finally, Los Angeles Capital Management LLC increased its stake in SpringWorks Therapeutics by 30.8% in the 4th quarter. Los Angeles Capital Management LLC now owns 61,760 shares of the company’s stock valued at $2,231,000 after buying an additional 14,548 shares during the last quarter.

SpringWorks Therapeutics Trading Down 0.2%

SWTX opened at $46.78 on Thursday. The company has a 50 day moving average of $44.67 and a 200 day moving average of $43.91. The company has a market cap of $3.52 billion, a PE ratio of -13.72 and a beta of 0.70. SpringWorks Therapeutics has a 12 month low of $28.21 and a 12 month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 51.10% and a negative net margin of 115.60%. The business had revenue of $49.09 million during the quarter, compared to the consensus estimate of $64.19 million. Research analysts forecast that SpringWorks Therapeutics will post -2.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Barclays reiterated an “equal weight” rating and issued a $47.00 price objective (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. HC Wainwright reiterated a “neutral” rating and issued a $47.00 price objective (down previously from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Guggenheim reiterated a “neutral” rating and issued a $47.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Wedbush reissued a “neutral” rating and set a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Finally, TD Cowen reissued a “hold” rating and set a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $52.57.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.